Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews · Oral medicine and oral cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 6 · 100%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Higher total dose radiotherapy (76.8 Gy over 6.4 weeks) vs conventional dose RT

Total mortality · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

Higher total dose radiotherapy (76.8 Gy over 6.4 weeks) showed no clear difference in total mortality compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
HR 1.08 [0.69, 1.70]
1 study
GRADE not reported

Higher total dose radiotherapy (76.8 Gy over 6.4 weeks) vs conventional dose RT

Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

Higher total dose radiotherapy (76.8 Gy over 6.4 weeks) showed no clear difference in locoregional control compared with conventional/standard total dose radiotherapy (72 Gy); GRADE not reported.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
HR 0.78 [0.55, 1.11]
1 study
GRADE not reported

Prophylactic valaciclovir (lower dose) vs Prophylactic valaciclovir (higher dose)

Presence/absence of HSV oral lesions · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)

Prophylactic valaciclovir (lower dose) showed no clear difference in presence/absence of HSV oral lesions compared with prophylactic valaciclovir (higher dose); GRADE not reported.

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
RR 0.23 [0.05, 1.03]
2 studies · 181 participants
GRADE not reported

Prophylactic valaciclovir (lower dose) vs Prophylactic valaciclovir (higher dose)

Viral isolates · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
Orlowski 2004: 182 throat swabs performed for patients receiving 500 mg of valaciclovir (n = 40) and 198 swabs for those receiving 1000 mg (n = 41); all of the cultures proved negative (1 trial, 81; not estimable).
1 study · 81 participants
GRADE not reported

Prophylactic valaciclovir (lower dose) vs Prophylactic valaciclovir (higher dose)

Adverse effects · Patients being treated for cancer (acute leukaemia; chemotherapy or stem-cell transplantation)

1 finding from 1 review

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
One study reported adverse effects (Warkentin 2002). Twenty patients allocated to receive high dose valaciclovir reported adverse effects (42%); for the low dose group this number was 27 (52%). Adverse effects were…
1 study · 100 participants
GRADE not reported

Low dose rate interstitial radiotherapy vs High dose rate interstitial radiotherapy

Locoregional control · People with primary squamous cell carcinoma of the oral cavity (ICD-O C01-C06) or oropharynx (ICD-O C09-C10); head and neck cancer trials…

Low dose rate interstitial radiotherapy showed no clear difference in locoregional control compared with high dose rate interstitial radiotherapy; GRADE not reported.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
HR 1.00 [0.16, 6.44]
1 study · 59 participants
GRADE not reported